GlassScriptPhysician profile
Jason A Black
NPI 1073587887
$37,807.63
in general payments reported to CMS, 2019-2025
70 companies · $2,880 in 2025
The $2,880 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,088 · 2021: $4,509 · 2022: $3,022 · 2023: $2,983 · 2024: $5,619 · 2025: $2,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,857 · Consulting Fee: $2,048 · Travel and Lodging: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.85 |
| Consulting Fee | $2,047.50 |
| Travel and Lodging | $1,577.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,409.64 | 2019-2024 | Xarelto |
| Janssen Global Services, LLC | $3,621.15 | 2024-2025 | |
| Abbvie INC. | $2,666.65 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,878.29 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,850.11 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $1,312.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,227.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $713.37 | 2019-2024 | Injectafer |
| Glaxosmithkline, LLC. | $690.33 | 2019-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $601.36 | 2021-2025 | Rexulti, Abilify Mycite |
| Collegium Pharmaceutical, INC. | $594.94 | 2019-2025 | Belbuca, Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $589.37 | 2021-2025 | |
| Allergan, INC. | $573.40 | 2019-2020 | |
| Pfizer INC. | $496.22 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.61 | 2019-2025 | Jardiance, Tradjenta |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $431.21 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.55 | 2019-2025 | Xifaxan, Relistor |
| Amarin Pharma, INC. | $303.62 | 2019-2021 | |
| Abbott Laboratories | $243.79 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $215.73 | 2019-2023 | |
| Radius Health, INC. | $212.51 | 2019-2023 | Tymlos |
| Eisai INC. | $208.31 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $178.42 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $172.50 | 2025 | |
| Sanofi-Aventis U.S. LLC | $140.47 | 2019-2025 | |
| Exact Sciences Corporation | $134.23 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $133.90 | 2022 | |
| Antares Pharma, INC. | $128.51 | 2019-2024 | Xyosted |
| Shockwave Medical, INC | $127.07 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $122.37 | 2019-2020 | |
| Almatica Pharma LLC | $118.56 | 2021-2025 | Loreev Xr |
| Si-Bone, INC. | $110.45 | 2023-2024 | |
| Lundbeck LLC | $106.65 | 2023-2025 | Rexulti |
| Circassia INC. | $93.25 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $87.34 | 2025 | Tlando |
| Zyla Life Sciences, INC. | $83.78 | 2019 | |
| Merck Sharp & Dohme LLC | $82.68 | 2019-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $79.18 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $78.35 | 2019-2022 | |
| Nevro Corp. | $75.44 | 2019-2023 | Senza |
| Medtronic, INC. | $75.44 | 2022-2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.06 | 2022-2025 | Caplyta |
| Horizon Therapeutics Plc | $63.10 | 2020-2021 | |
| Mylan Specialty L.P. | $57.12 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $55.67 | 2023 | Auvelity |
| Mannkind Corporation | $53.51 | 2019 | |
| Boston Scientific Corporation | $51.89 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.34 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $49.13 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Aytu Biopharma, INC. | $44.15 | 2019 | |
| Acerus Pharmaceuticals Corporation | $42.17 | 2022 | |
| Sumitomo Pharma America, INC. | $40.68 | 2025 | Gemtesa |
| Corcept Therapeutics | $38.55 | 2025 | Korlym |
| Harmony Biosciences LLC | $38.47 | 2024 | |
| Assertio Therapeutics, INC. | $38.26 | 2020 | |
| Viiv Healthcare Company | $37.59 | 2024 | Apretude |
| Evoke Pharma, INC. | $35.08 | 2024-2025 | |
| Tolmar, INC. | $33.95 | 2025 | Jatenzo |
| Scilex Pharmaceuticals INC. | $33.92 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $31.13 | 2021 | |
| Dexcom, INC. | $22.53 | 2021 | |
| Halozyme INC | $20.91 | 2023 | |
| Supernus Pharmaceuticals, INC. | $19.45 | 2019 | Tlando, Xyosted |
| Biohaven Pharmaceuticals, INC. | $19.43 | 2021 | |
| Astellas Pharma US INC | $19.00 | 2019 | |
| Baxter Healthcare | $18.09 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Currax Pharmaceuticals LLC | $16.70 | 2025 | Contrave |
| Intra-Sana Laboratories | $13.81 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Redhill Biopharma INC. | $12.35 | 2021 | |
| Gilead Sciences, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.